Semaglutide ishuga-inoderedza mishonga yakagadzirwa naNovo Nordisk yekurapa kwechirwere cheshuga 2. Muna Chikumi 2021, iyo FDA yakabvumidza Semaglutide yekushambadzira senge yekurasikirwa uremu mushonga (zita rekutengesa Wegovy). Mushonga iglucagon-like peptide 1 (GLP-1) receptor agonist inogona kutevedzera mhedzisiro yayo, kuderedza nzara, uye nekudaro kuderedza kudya uye kudya kwekoriori, saka inoshanda mukurasikirwa nehuremu.
Pamusoro pekushandiswa kurapa chirwere cheshuga 2 uye kufutisa, Semaglutide yakawanikwa zvakare kuchengetedza hutano hwemoyo, kuderedza njodzi yekenza, uye kubatsira kurega kunwa. Mukuwedzera, zvidzidzo zviviri zvenguva pfupi zvakaratidza kuti Semaglutide inogonawo kuderedza dambudziko rechirwere chepfungwa chisingaperi uye chirwere cheAlzheimer.
Ongororo dzakapfuura dzakaratidza kuti kurasikirwa uremu kunogona kubvisa zviratidzo zvemabvi osteoarthritis (kusanganisira marwadzo). Zvisinei, migumisiro yeGLP-1 receptor agonist kurasikirwa nemishonga yakadai seSemaglutide pamigumisiro yemabvi osteoarthritis muvanhu vakafuta haina kunyatsodzidza.
Musi waGumiguru 30, 2024, vaongorori kubva kuYunivhesiti yeCopenhagen neNovo Nordisk vakaburitsa bepa rekutsvagisa rakanzi: Kamwe-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis muNew England Journal of Medicine (NEJM), bhuku repamusoro rekurapa repasi rose.
Ichi chidzidzo chekliniki chakaratidza kuti semaglutide inogona kuderedza uremu uye kuderedza zvakanyanya marwadzo anokonzerwa nekufutisa-ane chokuita nemabvi arthritis (iyo analgesic effect yakaenzana neyeopioid), uye inovandudza kukwanisa kwavo kutora chikamu mumitambo. Ino inguva yekutanga zvakare kuti rudzi rutsva rwehuremu zvinodhaka, GLP-1 receptor agonist, yakasimbiswa kurapa arthritis.
Nguva yekutumira: Feb-27-2025